###begin article-title 0
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Effect of leptin infusion on insulin sensitivity and lipid metabolism in diet-induced lipodystrophy model mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 1185 1187 1185 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;</italic>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 436 440 <span type="species:ncbi:10090">mice</span>
###xml 463 468 <span type="species:ncbi:9606">human</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
###xml 705 709 <span type="species:ncbi:381124">corn</span>
###xml 768 772 <span type="species:ncbi:10090">mice</span>
###xml 824 828 <span type="species:ncbi:381124">corn</span>
###xml 918 922 <span type="species:ncbi:10090">mice</span>
###xml 974 978 <span type="species:ncbi:381124">corn</span>
###xml 1019 1025 <span type="species:ncbi:10090">murine</span>
###xml 1085 1089 <span type="species:ncbi:10090">mice</span>
Lipodystrophies are rare acquired and genetic disorders characterized by the complete or partial absence of body fat with a line of metabolic disorders. Previous studies demonstrated that dietary conjugated linoleic acid (CLA) induces hepatic steatosis and hyperinsulinemia through the drastic reduction of adipocytokine levels due to a paucity of adipose tissue in mice and the pathogenesis of these metabolic abnormalities in CLA-fed mice is similar to that in human lipodystrophy. The present study explores the effect of leptin infusion on the pathogenesis of diet-induced lipodystrophy in mice. C57BL/6N mice were assigned to three groups: (1) mice were fed a semisynthetic diet supplemented with 6% corn oil and infused PBS intraperitoneally (normal group), (2) mice were fed a semisynthetic diet supplemented with 4% corn oil plus 2% CLA and infused PBS intraperitoneally (lipodystrophy-control group), and (3) mice were fed a semisynthetic diet supplemented with 4% corn oil plus 2% CLA and infused recombinant murine leptin intraperitoneally (lipodystrophy-leptin group). All mice were fed normal or lipodystrophy model diets for 4 weeks and were infused intrapeneally 0 or 5 mug of leptin per day from third week of the feeding period for 1 week.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 230 234 <span type="species:ncbi:10090">mice</span>
The results indicate that leptin infusion can attenuate hepatic steatosis and hyperinsulinemia through the reduction of hepatic triglyceride synthesis and the improvement of insulin sensitivity in diet-induced lipodystrophy model mice.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
We expect the use of this model for clarifying the pathophysiology of lipodystrophy-induced metabolic abnormalities and evaluating the efficacy and safety of drug and dietary treatment.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 717 718 717 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 719 720 719 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 926 927 926 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1083 1085 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 765 771 <span type="species:ncbi:9606">humans</span>
###xml 989 992 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1002 1010 <span type="species:ncbi:9606">patients</span>
###xml 1020 1025 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recent advances in molecular and cell biology have shown that adipose tissue not only stores excess energy in the form of fat, but also secretes physiologically active substances called adipocytokines [1]. In obesity, it is well known that adipocytes, cells of adipose tissues, are increased and enlarged, and they secrete excess amounts of inflammatory adipocytokines, such as tumor necrosis factor-alpha [2] and monocyte chemoattractant protein-1 [3]. This induces insulin resistance, hyperinsulinemia, and fatty liver [4,5]. On the other hand, it is reported that the deficiency of adipocytes also induces type-2 diabetes due to a paucity of normally functioning adipocytokines such as leptin [6] and adiponectin [7,8]. This symptom is known as lipodystrophy in humans. Lipodystrophies are rare acquired and genetic disorders characterized by the complete or partial absence of body fat with a line of metabolic disorders [9,10]. Recent reports indicated that the clinical treatment of HIV-infected patients by using HIV-1 protease inhibitors also induces acquired lipodystrophy [10].
###end p 9
###begin p 10
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1326 1327 1326 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 131 136 <span type="species:ncbi:10090">mouse</span>
###xml 207 212 <span type="species:ncbi:10090">mouse</span>
###xml 234 239 <span type="species:ncbi:10090">mouse</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 873 877 <span type="species:ncbi:10090">mice</span>
###xml 1399 1403 <span type="species:ncbi:10090">mice</span>
###xml 1426 1431 <span type="species:ncbi:9606">human</span>
###xml 1476 1480 <span type="species:ncbi:10090">mice</span>
To understand the pathophysiology of lipodystrophy and evaluate the efficacy and safety of clinical treatments, several transgenic mouse models that mimic the features of lipodystrophy, such as aP2-SREBP-1c mouse [11-13] and A-ZIP/F1 mouse [14-16], have been established. Additionally, it has been reported that feeding of conjugated linoleic acid (CLA), a group of positional and geometric isomers of linoleic acid, with a low-fat diet also induces lipodystrophy, characterized by an increase in hepatic lipid content concomitant with a decrease in body fat mass in mice [17,18]. It has been suggested that lipodystrophy may occur in mice because they are too sensitive to the CLA-induced reduction in body fat [19,20]. We previously reported that short-term feeding of CLA decreased weights of adipose tissues and hepatic lipid levels without inducing adverse effects in mice [21]. Tsuboyama-Kasaoka, Miyazaki, Kasaoka, and Ezaki [22] also reported that increasing the amount of fat in a CLA-supplemented diet substantially reduces the lipodystrophy effect. These results indicate that dietary CLA induces fatty liver and hyperinsulinemia through the drastic reduction of adipocytokine levels due to a paucity of adipose tissue, but not through the direct induction of hepatic lipid synthesis and insulin resistance (Figure 1). Because the pathogenesis of these metabolic abnormalities in CLA-fed mice is similar to that in human lipodystrophy, we expect the use of CLA-fed mice as a diet-induced lipodystrophy model.
###end p 10
###begin p 11
Scheme showing possible mechanisms of CLA-induced lipodystrophy.
###end p 11
###begin p 12
###xml 275 281 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob/ob </italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 335 350 <span type="species:ncbi:10090">transgenic mice</span>
###xml 373 377 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
###xml 826 830 <span type="species:ncbi:10090">mice</span>
In the present study, we investigated the effects of leptin infusion on insulin sensitivity and lipid metabolism in diet-induced lipodystrophy model mice. Previous studies demonstrated that leptin treatment attenuated insulin resistance in genetically diabetic mice (such as ob/ob mice and MKR mice) [23,24] and in lipodystrophy model transgenic mice (such as aP2-SREBP-1c mice) [25]. In addition, Tsuboyama-Kasaoka, Takahashi, Tnemura, Kim, Tnage, Okuyama, Kasai, Ikemoto, and Ezaki [26] showed preliminary data indicating that leptin infusion lowers the levels of serum insulin and attenuates hepatocyte fat deposition in CLA-fed lipodystrophy model mice. To clarify the precise effect of leptin infusion, we measured hepatic enzyme activities in relation to lipid metabolism and tested insulin sensitivities in these model mice.
###end p 12
###begin title 13
Results and Discussion
###end title 13
###begin title 14
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Effect of leptin infusion on growth parameters in diet-induced lipodystrophy model mice
###end title 14
###begin p 15
###xml 47 48 47 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 56 57 56 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 483 487 <span type="species:ncbi:10090">mice</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
The experimental design is indicated in Figure 2. Table 1 shows the effect of leptin infusion on growth parameters in diet-induced lipodystrophy model mice. Although there was no significant difference in final body weight or food intake among groups, CLA-containing lipodystrophy model diets significantly increased the liver weight of mice, as has been reported elsewhere [17-20]. Leptin infusion alleviated, but not significantly, hepatomegaly in diet-induced lipodystrophy model mice. Weights of waist subcutaneous and abdominal (perirenal, epididymal, and omental) white adipose tissue (WAT) were significantly decreased in lipodystrophy model mice, and there was no significant effect of leptin infusion on WAT weights in this model.
###end p 15
###begin p 16
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Experimental design.</bold>
###xml 174 176 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;</italic>
###xml 21 25 <span type="species:ncbi:10090">Mice</span>
Experimental design. Mice were fed normal diet (normal group) or lipodystrophy model diets (control group and leptin group) for 4 weeks and were infused intrapeneally 0 or 5 mug of leptin per day for the final week of the 4-week feeding period.
###end p 16
###begin p 17
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Effect of leptin infusion on growth parameters in C57BL/6N mice
###end p 17
###begin p 18
###xml 0 5 0 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a, b </sup>
###xml 66 68 66 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
a, b Different superscript letters show significant difference at P < 0.05.
###end p 18
###begin title 19
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Effect of leptin infusion on hepatic triglyceride metabolism in diet-induced lipodystrophy model mice
###end title 19
###begin p 20
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10116">rats</span>
Figure 3 shows hepatic triglyceride levels and serum aspartate aminotransferase (AST) levels of C57BL/6N mice at the end of the experiment. The hepatic triglyceride level in mice fed the lipodystrophy model diet was 5-fold that in the mice fed a normal diet, and 1-week infusion of leptin resulted in a 62% attenuation of triglyceride accumulation in the liver. The activities of AST, one of the hepatic injury markers, in the serum of lipodystrophy model mice were markedly increased because of the development of hepatic steatosis. Leptin infusion to the rats fed lipodystrophy model diets, however, resulted in a 41% decrease of AST levels consistent with the attenuation of hepatic triglyceride accumulation.
###end p 20
###begin p 21
###xml 0 144 0 144 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of leptin infusion on hepatic triglyceride levels and serum alanine aminotransferase activities in diet-induced lipodystrophy model mice.</bold>
###xml 245 247 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;</italic>
###xml 355 359 352 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a, b</sup>
###xml 409 411 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 145 149 <span type="species:ncbi:10090">Mice</span>
Effect of leptin infusion on hepatic triglyceride levels and serum alanine aminotransferase activities in diet-induced lipodystrophy model mice. Mice were fed normal or lipodystrophy model diets for 4 weeks and were infused intrapeneally 0 or 5 mug of leptin per day f for the final week of the 4-week feeding period. Values are expressed as mean +/- SE. a, bDifferent letters show significant differences at P < 0.05. AST, alanine aminotransferase.
###end p 21
###begin p 22
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 663 671 663 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo </italic>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 694 695 694 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 785 787 785 787 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
###xml 890 894 <span type="species:ncbi:10090">mice</span>
Takahashi, Kushiro, Shinohara, and Ide [27] demonstrated that CLA increases the activity and mRNA levels of hepatic lipogenic enzymes; they suggested that enhanced lipogenesis is a principal mechanism of CLA-induced hepatic steatosis in mice. In this study, activities of fatty acid synthase (FAS) and malic enzyme (ME) were increased in the liver of mice fed the lipodystrophy model diet, as has been reported previously (Figure 4). Leptin infusion, however, did not change those lipogenic enzyme activities in diet-induced lipodystrophy model mice. We also measured the activities of phosphatidate phosphohydrolase (PAP), the key enzyme in the regulation of TG de novo synthesis [28] (Figure 4). The lipodystrophy model diet increased the activities of the membrane-bound forms of Mg2+-dependent PAP, but these activities were significantly suppressed by the leptin treatment in C57BL/6N mice. Therefore we supposed that hepatic steatosis induced by the lipodystrophy model diet was attenuated by leptin infusion partly through the suppression of triglyceride synthesis.
###end p 22
###begin p 23
###xml 0 133 0 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of leptin infusion on activities of enzymes related to lipid metabolism in the liver of diet-induced lipodystrophy model mice.</bold>
###xml 234 236 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;</italic>
###xml 342 346 339 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a, b</sup>
###xml 396 398 393 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 134 138 <span type="species:ncbi:10090">Mice</span>
Effect of leptin infusion on activities of enzymes related to lipid metabolism in the liver of diet-induced lipodystrophy model mice. Mice were fed normal or lipodystrophy model diets for 4 weeks and were infused intrapeneally 0 or 5 mug of leptin per day for the final week of the 4-week feeding period. Values are expressed as mean +/- SE. a, bDifferent letters show significant differences at P < 0.05. FAS, fatty acid synthase; ME, malic enzyme; PAP, phosphatidate phosphohydrolase.
###end p 23
###begin title 24
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Effect of leptin infusion on adipocytokine levels and insulin sensitivities in diet-induced lipodystrophy model mice
###end title 24
###begin p 25
###xml 19 20 19 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 829 830 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 998 999 998 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1146 1147 1146 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1314 1315 1314 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1550 1552 1550 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1553 1555 1553 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1754 1756 1754 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1757 1759 1757 1759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
###xml 342 348 <span type="species:ncbi:9606">humans</span>
###xml 728 732 <span type="species:ncbi:10090">mice</span>
###xml 940 944 <span type="species:ncbi:10090">mice</span>
###xml 1062 1066 <span type="species:ncbi:10090">mice</span>
###xml 1301 1305 <span type="species:ncbi:10090">mice</span>
###xml 1748 1752 <span type="species:ncbi:10090">mice</span>
As shown in Figure 5, serum levels of adiponectin and leptin were drastically decreased in mice fed the CLA-containing lipodystrophy model diet, as previously reported [17-20]. Adiponectin and leptin are both abundantly secreted from adipose tissue and have several physiological functions, including the regulation of insulin sensitivity in humans and animals. Therefore it has been reported that the deficiency of adipocytokine secretion induced by a paucity of adipose tissue would be a cause of lipodystrophy, which is characterized by a severe insulin resistance and leads to hyperinsulinemia and hepatic steatosis [19,20]. In the present study, hepatic steatosis and hyperinsulinemia were alleviated by leptin infusion in mice fed the lipodystrophy model diet, concomitant with the alleviation of leptin deficiency (Figure 5). However, leptin infusion did not affect adiopnectin levels, compared with those seen with PBS injection in mice fed the lipodystrophy model diet. As shown in Figure 6, the insulin-mediated glucose lowering effect was impaired in mice fed the lipodystrophy model diet, consistent with serum insulin levels (Figure 5). However, the insulin resistance induced by the lipodystrophy model diet was markedly alleviated by leptin infusion in diet-induced lipodystrophy model mice (Figure 6). These results suggest that leptin treatment attenuates hepatic steatosis and hyperinsulinemia through the alleviation of insulin resistance in the diet-induced lipodystrophy model, as has been shown in various lipodystrophy models [23-25]. Although previous reports demonstrated that treatment with rosiglitazone (an insulin sensitizer) can improves insulin resistance concomitant with an increase of adiponectin level in CLA-fed mice [29,30], our results suggest that leptin replacement is sufficient to alleviate hepatic steatosis and hyperinsulinemia in this diet-induced lipodystrophy model.
###end p 25
###begin p 26
###xml 0 110 0 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of leptin infusion on serum adipocytokines and insulin levels in diet-induced lipodystrophy model mice.</bold>
###xml 211 213 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;</italic>
###xml 319 323 316 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a, b</sup>
###xml 373 375 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 111 115 <span type="species:ncbi:10090">Mice</span>
Effect of leptin infusion on serum adipocytokines and insulin levels in diet-induced lipodystrophy model mice. Mice were fed normal or lipodystrophy model diets for 4 weeks and were infused intrapeneally 0 or 5 mug of leptin per day for the final week of the 4-week feeding period. Values are expressed as mean +/- SE. a, bDifferent letters show significant differences at P < 0.05.
###end p 26
###begin p 27
###xml 0 92 0 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of leptin infusion on insulin sensitivities in diet-induced lipodystrophy model mice.</bold>
###xml 193 195 193 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;</italic>
###xml 408 410 405 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 93 97 <span type="species:ncbi:10090">Mice</span>
Effect of leptin infusion on insulin sensitivities in diet-induced lipodystrophy model mice. Mice were fed normal or lipodystrophy model diets for 4 weeks and were infused intrapeneally 0 or 5 mug of leptin per day for the final week of the 4-week feeding period. Blood glucose was measured at the indicated time points. Values are expressed as mean +/- SE. Means at a time without a common letter differ at P < 0.05.
###end p 27
###begin title 28
Conclusion
###end title 28
###begin p 29
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 346 350 <span type="species:ncbi:10090">mice</span>
The present study explored the effect of leptin infusion on the pathogenesis of diet-induced lipodystrophy in mice. The results indicate that leptin infusion can attenuate hepatic steatosis and hyperinsulinemia through the reduction of hepatic triglyceride synthesis and the improvement of insulin sensitivity in diet-induced lipodystrophy model mice. We expect the use of this model for clarifying the pathophysiology of lipodystrophy-induced metabolic abnormalities and evaluating the efficacy and safety of drug and dietary treatment.
###end p 29
###begin title 30
Methods
###end title 30
###begin title 31
Animals and diets
###end title 31
###begin p 32
###xml 785 787 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;</italic>
###xml 963 965 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 164 168 <span type="species:ncbi:10090">mice</span>
###xml 320 324 <span type="species:ncbi:10090">Mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:381124">corn</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:381124">corn</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
###xml 723 727 <span type="species:ncbi:381124">corn</span>
###xml 768 774 <span type="species:ncbi:10090">murine</span>
###xml 1255 1259 <span type="species:ncbi:10090">mice</span>
###xml 1362 1366 <span type="species:ncbi:10090">mice</span>
All aspects of the experiment were conducted according to the guidelines provided by the Ethical Committee of Experimental Animal Care at Saga University. C57BL/6N mice (Kyudo Co., Ltd., Saga, Japan) were housed individually in metal cages in a temperature-controlled room (24degreesC) under a 12-hour light/dark cycle. Mice were assigned to three groups (3-6 mice each): (1) mice were fed a semisynthetic diet supplemented with 6% corn oil and infused PBS (Gibco, Tokyo, Japan) intraperitoneally (normal group), (2) mice were fed a semisynthetic diet supplemented with 4% corn oil plus 2% CLA and infused PBS intraperitoneally (lipodystrophy-control group), and (3) mice were fed a semisynthetic diet supplemented with 4% corn oil plus 2% CLA and infused recombinant murine leptin (5 mug/day, PeproTech EC, London, United Kingdom) intraperitoneally (lipodystrophy-leptin group). The semisynthetic diets were prepared according to recommendations of the AIN-93G [31] and contained (in weight %) casein, 20; fat, 6; alpha-cornstarch, 13.2; vitamin mixture (AIN-93trade mark), 1; mineral mixture (AIN-93Gtrade mark), 3.5; L-cystein, 0.3; choline bitartrate, 0.25; cellulose, 5; sucrose, 10; tert-buthyhydroquinone, 0.0014; and beta-cornstarch, 40.7486. The mice received the diets ad libitum using Rodent CAFE (KBT Oriental Co. Ltd., Saga, Japan) for 4 weeks. The mice were killed by exsanguination of the heart, and serum was separated from the blood. Liver and WATs (perirenal, epididymal, omental, and waist subcutaneous) were also excised for analysis.
###end p 32
###begin title 33
Analysis of hepatic triglyceride and serum parameters
###end title 33
###begin p 34
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 258 263 <span type="species:ncbi:10090">mouse</span>
Liver lipids were extracted according to the method of Folch, Lee, and Sloane-Stanley [32], and the concentrations of triglyceride were measured using the methods of Fletcher [33]. Serum insulin, adiponectin, and leptin levels were measured using commercial mouse ELISA kits (Shibayagi Co. Ltd., Gunma, Japan; Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan; and Morinaga Co. Ltd., Yokohama, Japan, respectively). Activities of AST in serum were measured using commercial enzyme assay kits (Wako Pure Chemicals, Tokyo, Japan).
###end p 34
###begin title 35
Measurement of hepatic enzyme activities
###end title 35
###begin p 36
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 334 340 <span type="species:ncbi:9913">bovine</span>
A piece of liver was homogenized insix volumes of a 0.25-M sucrose solution that contained 1 mM EDTA in a 10-mM Tris-HCL buffer (pH 7.4). Fractions of cytosol and microsomes were obtained as previously described [34]. The protein concentration was determined according to the method of Lowry, rosebrough, Farr, and Randall [35], with bovine serum albumin used as the standard. The enzyme activities of ME (EC 1.1.1.40) [36] and FAS (EC 2.3.1.85) [37] in the liver cytosol fraction and phosphatidate phosphohydrolase (EC 3.1.3.4) [38] in the liver microsomal fraction were determined as described.
###end p 36
###begin title 37
Insulin tolerance test
###end title 37
###begin p 38
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
At the end of the feeding period, human insulin (Humulin R; Eli Lilly Japan K.K., Kobe, Japan) was injected intraperitoneally (0.75 mU/g body weight) to all mice. Blood glucose was measured on samples obtained from tail tip before and 30, 60, 90, and 120 min after insulin injection. Blood glucose concentrations were measured using the GLUCOCARDtrade mark G meter (Arkray, Kyoto, Japan).
###end p 38
###begin title 39
Statistical analysis
###end title 39
###begin p 40
###xml 151 153 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 205 207 203 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
All values are expressed as means +/- SE. Data were analyzed by one-way ANOVA, and all differences were inspected by Duncan's new multiple-range test [39]. Differences were considered to be significant at P < 0.05.
###end p 40
###begin title 41
List of abbreviations
###end title 41
###begin p 42
AST, aspartate aminotransferase; CLA, conjugated linoleic acid; FAS, fatty acid synthase; ME, malic enzyme; PAP, phosphatidate phosphohydrolase; WAT, white adipose tissue.
###end p 42
###begin title 43
Competing interests
###end title 43
###begin p 44
The author(s) declare that they have no competing interests.
###end p 44
###begin title 45
Authors' contributions
###end title 45
###begin p 46
KN contributed in planning, experimental work, analysis and publication of results. NI contributed in planning, experimental work, analysis, and discussion. YU contributed in experimental work and analysis. KH contributed in experimental work and analysis. BS contributed in planning of the experiment and in discussion of results. YMW contributed in planning of the experiment and in discussion of results. TY contributed in planning of the experiment, discussion of results, and providing funding for the study. All authors read and approved the final manuscript.
###end p 46
###begin title 47
Acknowledgements
###end title 47
###begin p 48
This work was supported by a research grant from the Japanese Ministry of Education, Culture, Sports, Science and Technology. We thank Miho Nakagawa for technical assistance and the Nisshin OilliO Group Ltd. (Yokosuka, Japan) for providing sample oils.
###end p 48
###begin article-title 49
Molecular Mechanism of Metabolic Syndrome X: Contribution of Adipocytokines and adipocyte-derived bioactive substances
###end article-title 49
###begin article-title 50
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance
###end article-title 50
###begin article-title 51
Monocyte chemoattractant protein 1 in obesity and insulin resistance
###end article-title 51
###begin article-title 52
###xml 63 68 <span type="species:ncbi:9606">human</span>
Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha
###end article-title 52
###begin article-title 53
MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity
###end article-title 53
###begin article-title 54
Leptin
###end article-title 54
###begin article-title 55
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity
###end article-title 55
###begin article-title 56
###xml 168 182 <span type="species:ncbi:9544">rhesus monkeys</span>
Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys
###end article-title 56
###begin article-title 57
Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue
###end article-title 57
###begin article-title 58
Lipodystrophy: lessons in lipid and energy metabolism
###end article-title 58
###begin article-title 59
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy
###end article-title 59
###begin article-title 60
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus
###end article-title 60
###begin article-title 61
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver
###end article-title 61
###begin article-title 62
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
Life without white fat: a transgenic mouse
###end article-title 62
###begin article-title 63
###xml 10 14 <span type="species:ncbi:10090">mice</span>
A-ZIP/F-1 mice lacking white fat: a model for understanding lipoatrophic diabetes
###end article-title 63
###begin article-title 64
###xml 74 78 <span type="species:ncbi:10090">mice</span>
Lack of responses to a beta3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice
###end article-title 64
###begin article-title 65
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
Dietary trans-10, cis-12 conjugated linoleic acid induces hyperinsulinemia and fatty liver in the mouse
###end article-title 65
###begin article-title 66
Perspective on the safety and effectiveness of conjugated linoleic acid
###end article-title 66
###begin article-title 67
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Conjugated linoleic acid deteriorates insulin resistance in obese/diabetic mice in association with decreased production of adiponectin and leptin
###end article-title 67
###begin article-title 68
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
Hyperinsulinaemia triggered by dietary conjugated linoleic acid is associated with a decrease in leptin and adiponectin plasma levels and pancreatic beta cell hyperplasia in the mouse
###end article-title 68
###begin article-title 69
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Short-term feeding of conjugated linoleic acid does not induce hepatic steatosis in C57BL/6J mice
###end article-title 69
###begin article-title 70
###xml 102 106 <span type="species:ncbi:10090">mice</span>
Increasing the amount of fat in a conjugated linoleic acid-supplemented diet reduces lipodystrophy in mice
###end article-title 70
###begin article-title 71
###xml 61 65 <span type="species:ncbi:10090">mice</span>
A leptin dose-response study in obese (ob/ob) and lean (+/?) mice
###end article-title 71
###begin article-title 72
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes
###end article-title 72
###begin article-title 73
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
###end article-title 73
###begin article-title 74
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice
###end article-title 74
###begin article-title 75
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Activity and mRNA levels of enzymes involved in hepatic fatty acid synthesis and oxidation in mice fed conjugated linoleic acid
###end article-title 75
###begin article-title 76
Glycerolipid biosynthesis in eukaryotes
###end article-title 76
###begin article-title 77
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Maintenance of adiponectin attenuates insulin resistance induced by dietary conjugated linoleic acid in mice
###end article-title 77
###begin article-title 78
###xml 136 140 <span type="species:ncbi:10090">mice</span>
Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice
###end article-title 78
###begin article-title 79
AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet
###end article-title 79
###begin article-title 80
A simple method for the isolation and purification of total lipids from animal tissues
###end article-title 80
###begin article-title 81
A colorimetric method for estimation of serum triglycerides
###end article-title 81
###begin article-title 82
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fa/fa</italic>
###xml 95 99 <span type="species:ncbi:10116">rats</span>
Dietary conjugated linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats
###end article-title 82
###begin article-title 83
Protein measurement with the folin phenol reagent
###end article-title 83
###begin article-title 84
###xml 44 49 <span type="species:ncbi:4565">wheat</span>
Malic enzyme: malic enzymes from pigeon and wheat germ
###end article-title 84
###begin article-title 85
###xml 105 108 <span type="species:ncbi:10116">rat</span>
Effect of prior nutritional status on the activity of lipogenic enzymes in primary monolayer cultures of rat hepatocytes
###end article-title 85
###begin article-title 86
###xml 47 50 <span type="species:ncbi:10116">rat</span>
Mg dependent phosphatidate phosphohydrolase of rat lung: Development of an assay employing a defined chemical substrate which reflects phosphohydrolase activity measured using membrane-bound and substrate
###end article-title 86
###begin article-title 87
Multiple range and multiple F tests
###end article-title 87

